Blog
RSS FeedPosted by Michael Wonder on 23 May 2022
Draft CADTH recommendation for Spinraza (nusinersen sodium) fails adults in need of treatment for spinal muscular atrophy
20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – ...
Posted by Michael Wonder on 12 May 2022
CADTH expands scientific advice program to include advice on real world evidence
28 April 2022 - CADTH is expanding its scientific advice program to include applications for advice on real world evidence generation ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 05 Apr 2022
CADTH Strategy 2022-2025: anticipate, innovate and transform
5 April 2022 - CADTH is pleased to share Ahead of the Curve: Shaping Future-Ready Heath Systems, the agency's new ...
Posted by Michael Wonder on 21 Mar 2022
CADTH releases its annual list of health technology trends to watch
18 March 2022 - New horizon scan report offers insights on health technology trends that have the potential to harness ...
Posted by Michael Wonder on 18 Oct 2021
Alnylam receives positive reimbursement recommendation from the CADTH for use of Givlaari for the treatment of acute hepatic porphyria in adults
18 October 2021 - Givlaari reduces chronic pain, improves quality of life and is the first and only therapy proven ...
Posted by Michael Wonder on 12 Oct 2021
Outdated criteria for drug plan reimbursement obstruct evidence based care
12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...
Posted by Michael Wonder on 02 Sep 2021
A collaborative pilot on current awareness alerts for disinvestment and horizon scanning
31 August 2021 - In 2019, members of the Health Technology Assessment international Interest Group for Disinvestment and Early Awareness and ...
Posted by Michael Wonder on 30 Aug 2021
Evrysdi (risdiplam) receives CADTH reimbursement recommendation for some patients with spinal muscular atrophy
30 August 2021 - Roche Canada today announced that the CADTH Canadian Drug Expert Committee has issued its final recommendation ...
Posted by Michael Wonder on 22 Jul 2021
Dupixent (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
22 July 2021 - Recommendation supported by multiple clinical trials that demonstrated a reduced frequency of asthma exacerbations compared to placebo, ...
Posted by Michael Wonder on 29 Apr 2021
Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review
26 April 2021 - The objective was to describe the type and level of ethical integration in published health technology assessment ...
Posted by Michael Wonder on 04 Mar 2021
Ofev (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases
4 March 2021 - Ofev is the first treatment available in Canada for chronic fibrosing interstitial lung diseases with a progressive ...
Posted by Michael Wonder on 11 Feb 2021
An institutional ethnographic analysis of public and patient engagement activities at a national health technology assessment agency
9 February 2021 - The practice of public and patient engagement in health technology assessment has spread worldwide, yet gaps in ...
Posted by Michael Wonder on 07 Feb 2021
Patient and public involvement in health technology assessment: update of a systematic review of international experiences
5 February 2021 - This paper summarises the current evidence on patient and public involvement in health technology assessment in order ...
Posted by Michael Wonder on 24 Jan 2021
Creating a patient and community advisory committee at the Canadian Agency for Drugs and Technologies in Health
22 January 2021 - In recognition of patients’ roles using, and contributing to, a publicly funded health system, the Canadian Agency ...